Author:
Holle Julia U.,Moosig Frank
Publisher
Springer Science and Business Media LLC
Reference44 articles.
1. Hellmich B, Lamprecht P, Spearpoint P, Gotte D, Deichmann A, Buchholz I et al (2021) New insights into the epidemiology of ANCA-associated vasculitides in Germany: results from a claims data study. Rheumatology 60(10):4868–4873
2. Hellmich B, Sanchez-Alamo B, Schirmer JH, Berti A, Blockmans D, Cid MC et al (2023) EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis
3. Kidney Disease (2024) KDIGO 2024 clinical practice guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis. Kidney Int 105(3S):S71–S116
4. Little MA, Nightingale P, Verburgh CA, Hauser T, De Groot K, Savage C et al (2010) Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 69(6):1036–1043
5. Sanchez Alamo B, Moi L, Bajema I, Faurschou M, Flossmann O, Hauser T et al (2023) Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis. Nephrol Dial Transplant 38(7):1655–1665